It seems barely a week goes by without a UK firm falling prey to an opportunistic takeover approach. Typically, the bidders are non-UK and the targets are small and mid-cap companies.

Many UK stocks trade on cheap valuations and unless the market recognises their attractions and bids up the price, they could be vulnerable to takeovers.

Private equity companies, in particular, are sitting on lots of cash that can be used for deals. Predictions from various economists that the UK will avoid recession and recent government stability under Rishi Sunak won’t have gone unnoticed by overseas buyers.

On 17 April, a private equity consortium led by CVC proposed to pay 387p per share for London-listed payments group Network International (NETW). Four days later, a 400p per share counter proposal was made by Canadian investment group Brookfield, which owns the iconic Canary Wharf development in London’s Docklands and last year snapped up household services company Homeserve for £4.1 billion.

Also on 21 April, private equity group Cap10 made an all-cash offer for energy services firm Sureserve (SUR:AIM). On 24 April, telemedicine provider Medica (MGP:AIM) received a bid from private equity firm IK Investment Partners.

In the space of a few days, investors in all three firms have seen the potential for long-term investment returns vanish in exchange for a short-term pop in the shares.

In a rare case, Louise Kernohan and Georgina Cooper, fund managers at Newton Investment Management, have spoken out against the supposed attraction of EQT Partners’ £4.6 billion takeover offer for Dechra Pharmaceuticals (DPH).

‘We do not think the price announced under the terms of the possible offer is an appropriate or fair reflection of the value of Dechra Pharmaceuticals,’ say the managers.

‘The possible offer appears opportunistic, and we don’t believe it takes into consideration the recent strategic enhancements of the business and the value of the pipeline, with the recent acquisitions of Piedmont Animal Health and Med-Pharmex, and the licensing agreement with Akston Biosciences.’

However, takeovers aren’t the only factor reducing the number of UK listed companies – some firms are quitting the market of their own accord saying it no longer makes financial sense to remain quoted.

Technology investment company Asimilar (ASLR:AIM) revealed plans to delist from AIM to reduce costs, sending its share price down nearly 40%. Business services firm iEnergizer (IBPO:AIM) made a similar announcement sending its shares crashing 80% in a day.

One senior City investor contacted Shares to question the legality of such announcements, highlighting the lack of redress for minority shareholders whose investments have lost so much value literally overnight.

‹ Previous2023-04-27Next ›